The business of healthcare is the top of this week’s Innovation Partners BioBlog. AllianceRx Walgreens selects Inovalon for its new cloud-based specialty pharmacy, and there’s a move afoot to learn from retail giants like Amazon and apply the lessons to health organization management. Meanwhile,
This week’s Innovation Partners BioBlog focuses on oncology updates. The genome for a rare soft tissue tumor affecting infants has been sequenced, opening the doors for potential treatments. The FDA listed two initiatives targeting generic cancer drugs, and ASCO endorsed integrative oncology
Happy Father’s Day! In this week’s Innovation Partners BioBlog, we look at how the changing world of drug prices and health care laws impact pricing. U.S. drug prices fell but may rise sharply depending on future marketplace events. New markets are open now for Paxman’s scalp cooling product, and
Our focus this week is on the pharmaceutical industry with reports from the ASCO conference shaking up stocks, improving the outlook for some while downgrading others. Many companies are announcing results, cuts, and progress with key oncology drugs this week. Check out the Innovation Partners
Drug costs are in the spotlight this week from many quarters. First, drugmakers called out by the Trump Administration for blocking generics are also included in a Kaiser Health study that found that they increased prices by double digits since 2012. The so-called ‘right to try’ bill passed the
Health insurance is in the news this week as insurers file their 2019 rate requests for Affordable Care Act Exchanges. The bad news: rates appear to be going up across many companies and states. The good news: The ACA appears to have helped more young women receive an earlier cancer diagnosis thanks
Major news this week as President Trump launches “American Patients First” to bring down healthcare costs. California advanced a bill to socialize healthcare prices, while Oregon looks to reinstate its own state-based insurance exchange as ACA fees and other issue force them to seek alternatives.
A $1.5 million drug? Yes, according to experts. The high cost of drugs is in the news this week with gene therapy for hemophilia expected to cost over $1 million, President Trump making a speech about drug prices, and indication-based pricing all making the headlines. Read on for more from this